Comment on “Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)”

Benzer Materyaller

• Neoadjuvant Chemoradiation with IMRT in Resectable and Borderline Resectable Pancreatic Cancer
  Yazar:: Kharofa, Jordan, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
  Yazar:: Hu, Qiancheng, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
  Yazar:: Blazer, Marlo, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
  Yazar:: Katherine V. Trinh, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-09-01)
• Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
  Yazar:: Trinh, Katherine V., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)